Oral Administration of Hyperimmune Eggs Induces Mucosal IgA Responses, Anti-Idiotypic Antibodies, and HIV-1 Neutralizing Activity: A Proof-of-Concept Preclinical Study

13 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

The development of effective mucosal vaccination strategies against human immunodeficiency virus type 1 (HIV-1) remains a major challenge. This study investigated whether oral administration of hyperimmune anti-HIV-1 gp120 immunoglobulin Y (IgY) could induce mucosal and systemic immune responses in outbred felines through an anti-idiotypic network mechanism.
A controlled immunization study involving 42 cats (18 immunized and 24 controls) was conducted to evaluate mucosal anti-gp120 IgA responses. In addition, a proof-of-concept cohort was used to investigate anti-idiotypic antibody (Ab-3) induction, competitive inhibition, and HIV-1 neutralization.
Anti-gp120 IgA antibodies were detected in saliva from immunized animals but were absent or present at low levels in controls, indicating activation of mucosal immunity. All immunized cats developed detectable Ab-3 responses against HIV-1 gp120.
Competitive inhibition assays demonstrated specific in hibition of gp120-related interactions, supporting the presence of biologically relevant anti-idiotypic antibodies. Furthermore, sera from immunized animals significantly reduced HIV-1 infectivity in a TZM-bl luciferase-based neutralization assay, with viral inhibition exceeding 60% at selected dilutions.

Clinical Editorial

bioRxiv (Biomedical Preprints) published a clinical update in Research Highlights on 13 Jul 2026.

The item focuses on Oral Administration of Hyperimmune Eggs Induces Mucosal IgA Responses, Anti-Idiotypic Antibodies, and HIV-1 Neutralizing Activity: A Proof-of-Concept Preclinical Study.

Review the original article for the full source wording and details.